Sign inJoin
Company / Finance

Aethlon Medical, Inc.

AEMD · NASDAQ

AEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matter.

FollowAdd to WatchlistAsk Question
NASDAQAEMDCoverage BootstrapMedical DevicesClinical StageHemopurifier
Latest ReportMay 14, 2026Aethlon Medical: the blood-filter high-risk thesis racing a $7 million cash clockView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 company reports
Latest Thesis

Aethlon Medical: the blood-filter high-risk thesis racing a $7 million cash clock

AEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matter.

May 14, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Aethlon Medical, Inc.Medical: the blood-filter high-risk thesis racing a $7 million cMay 14, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Aethlon Medical: the blood-filter high-risk thesis racing a $7 million cash clockAEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matter.NASDAQMay 14, 2026Research reportReadSlides